Home Biotechnology NeuClone Pty Ltd
N

NeuClone Pty Ltd

Profile managed by Bizz Id
Australia

Description

NeuClone is an Australian clinical-stage biopharmaceutical company developing monoclonal antibody biosimilars, including ustekinumab, trastuzumab and denosumab, using its own NeuCHO cell expression system.

Products

8 products
Adalimumab

Biosimilar to Humira. Late preclinical.

Under development

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Denosumab

Biosimilar to Prolia/Xgeva. Preclinical (process scale-up).

Under development

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Nivolumab

Biosimilar to Opdivo. Late preclinical.

Under development

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Palivizumab

Biosimilar to Synagis. Preclinical (process scale-up).

Under development

Finished product (FDF)

Verified on 2026-10-21

Palivizumab: see suppliers →

Pembrolizumab

Biosimilar to Keytruda. Preclinical (process scale-up).

Under development

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Pertuzumab

Biosimilar to Perjeta. Preclinical (process scale-up).

Under development

Finished product (FDF)

Verified on 2026-10-21

Pertuzumab: see suppliers →

Trastuzumab

Biosimilar to Herceptin. Phase 1 (2018).

Under development

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Ustekinumab

Biosimilar to Stelara. Phase 1 (2019).

Under development

Finished product (FDF)

Verified on 2026-10-21

Ustekinumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free